CA2861261A1 - Non-aqueous liquid composition - Google Patents

Non-aqueous liquid composition Download PDF

Info

Publication number
CA2861261A1
CA2861261A1 CA 2861261 CA2861261A CA2861261A1 CA 2861261 A1 CA2861261 A1 CA 2861261A1 CA 2861261 CA2861261 CA 2861261 CA 2861261 A CA2861261 A CA 2861261A CA 2861261 A1 CA2861261 A1 CA 2861261A1
Authority
CA
Canada
Prior art keywords
aqueous liquid
preparation
liquid composition
drug
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2861261
Other languages
English (en)
French (fr)
Inventor
Kazuhito Yamada
Arto Urtti
Mechthild BURMESTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CA2861261A1 publication Critical patent/CA2861261A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA 2861261 2012-01-31 2013-01-30 Non-aqueous liquid composition Abandoned CA2861261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-018062 2012-01-31
JP2012018062 2012-01-31
PCT/JP2013/051951 WO2013115201A1 (ja) 2012-01-31 2013-01-30 非水性液体組成物

Publications (1)

Publication Number Publication Date
CA2861261A1 true CA2861261A1 (en) 2013-08-08

Family

ID=48905235

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2861261 Abandoned CA2861261A1 (en) 2012-01-31 2013-01-30 Non-aqueous liquid composition

Country Status (12)

Country Link
US (1) US20150011518A1 (cg-RX-API-DMAC7.html)
EP (1) EP2810657B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013177372A (cg-RX-API-DMAC7.html)
KR (1) KR20150000874A (cg-RX-API-DMAC7.html)
CN (1) CN104080478A (cg-RX-API-DMAC7.html)
CA (1) CA2861261A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491453A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN06911A (cg-RX-API-DMAC7.html)
PH (1) PH12014501689A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201606271RA (cg-RX-API-DMAC7.html)
TW (1) TW201336526A (cg-RX-API-DMAC7.html)
WO (1) WO2013115201A1 (cg-RX-API-DMAC7.html)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
AU6919598A (en) * 1997-04-17 1998-11-13 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4496406B2 (ja) 2003-03-07 2010-07-07 参天製薬株式会社 4−ピリジルアルキルチオ基を置換基として有する新規化合物
CN1897918A (zh) * 2003-11-17 2007-01-17 阿尔萨公司 包含两亲性分子作为混悬载体的组合物和剂型
JP4626353B2 (ja) 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
EP1843746B1 (en) * 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
PL1845942T3 (pl) * 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
AU2005325510B2 (en) * 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
JP4585978B2 (ja) 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP4834441B2 (ja) 2005-03-31 2011-12-14 参天製薬株式会社 ピリミジニルアルキルチオ基を有する新規環式化合物
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
JP4825636B2 (ja) 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2,3,4−テトラヒドロキノキサリン誘導体
KR20090086539A (ko) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
EP2128156A4 (en) 2007-01-29 2011-05-18 Santen Pharmaceutical Co Ltd NEW OXADIAZOL DERIVATIVES AND THIADIAZONE DERIVATIVES WITH THE NEOVASCULARIZATION HEMMENDER EFFECT
EP2151436B1 (en) 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2009035068A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規1,3,3-トリメチル-7-フェニル-3,4-ジヒドロ-1h-キノキサリン-2-オン誘導体
AU2010271746B2 (en) 2009-07-17 2014-07-03 Santen Pharmaceutical Co., Ltd. 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
PH12014501689A1 (en) 2014-10-20
EP2810657A4 (en) 2015-07-29
US20150011518A1 (en) 2015-01-08
EA201491453A1 (ru) 2014-12-30
WO2013115201A1 (ja) 2013-08-08
IN2014DN06911A (cg-RX-API-DMAC7.html) 2015-05-15
EP2810657B1 (en) 2016-09-21
SG10201606271RA (en) 2016-09-29
SG11201404230QA (en) 2014-10-30
KR20150000874A (ko) 2015-01-05
CN104080478A (zh) 2014-10-01
TW201336526A (zh) 2013-09-16
EP2810657A1 (en) 2014-12-10
JP2013177372A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
EP3843704B1 (en) Emulsion formulations of multikinase inhibitors
AU2017228608C1 (en) Injectable preparation
Boyd et al. Hexosomes formed from glycerate surfactants—Formulation as a colloidal carrier for irinotecan
CA2908571C (en) Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
AU2012283381B2 (en) A new therapeutical composition containing apomorphine as active ingredient
CN107257680A (zh) 用于眼科药物递送的自乳化药物递送体系(sedds)
MX2012003985A (es) Composiciones topicas tetraciclina.
CN102740833A (zh) 吉西他滨衍生物的肠胃外制剂
JP7781998B2 (ja) Jak阻害剤およびラウレス-4を含有する局所配合物
JP2016529308A (ja) フルベストラント組成物
WO2016104889A1 (en) Composition for a self-emulsifying drug delivery system comprising dutasteride
Piao et al. Formulation and in vivo human bioavailability of dissolving tablets containing a self-nanoemulsifying itraconazole solid dispersion without precipitation in simulated gastrointestinal fluid
KR20050099311A (ko) 주사제용 항암제 조성물
KR101996597B1 (ko) 두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
ES2276110T3 (es) Formulacion farmaceutica que incluye un inhibidor de renina no peptidico y un tensioactivo.
WO2008087076A1 (en) Pharmaceutical composition of improved stability containing taxane derivatives
JP2013199475A (ja) 水性医薬組成物
EP2810657B1 (en) Non-aqueous liquid composition
CN102451176B (zh) 多西紫杉烷/类固醇复合物
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤
CN101912362B (zh) 一种替尼泊苷静脉注射用脂肪乳预乳化浓缩液及其制备方法
CN101106995B (zh) 在非水极性溶剂中增加溶解度的10-羟基喜树碱类化合物的药物制剂
EP4447930A1 (en) Stable formulations of shr0302
EP3331567B1 (en) Stabilized injectable emulsion of propofol and ketamine
CN103228280B (zh) 包含瑞伐拉赞或其盐的可注射液体组合物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180130